End-Stage Kidney Disease Treatment Market Report

Global End-Stage Kidney Disease Treatment Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Jun 08, 2022
  • PAGES：214
  • REPORT CODE：GMM844659
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • End-Stage Kidney Disease Treatment market report explains the definition, types, applications, major countries, and major players of the End-Stage Kidney Disease Treatment market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • F Hoffmann-La Roche Ltd

    • CTI BioPharma Corp

    • BLR Bio LLC

    • VESSL Therapeutics Ltd

    • Novartis AG

    • Prolong Pharmaceuticals LLC

    By Type:

    • MK-3866

    • Pacritinib

    • Sanguinate

    • Tesidolumab

    • Others

    By End-User:

    • Clinic

    • Hospital

    • Others

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global End-Stage Kidney Disease Treatment Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 End-Stage Kidney Disease Treatment Outlook to 2028- Original Forecasts

    • 2.2 End-Stage Kidney Disease Treatment Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term End-Stage Kidney Disease Treatment Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global End-Stage Kidney Disease Treatment Market- Recent Developments

    • 6.1 End-Stage Kidney Disease Treatment Market News and Developments

    • 6.2 End-Stage Kidney Disease Treatment Market Deals Landscape

    7 End-Stage Kidney Disease Treatment Raw Materials and Cost Structure Analysis

    • 7.1 End-Stage Kidney Disease Treatment Key Raw Materials

    • 7.2 End-Stage Kidney Disease Treatment Price Trend of Key Raw Materials

    • 7.3 End-Stage Kidney Disease Treatment Key Suppliers of Raw Materials

    • 7.4 End-Stage Kidney Disease Treatment Market Concentration Rate of Raw Materials

    • 7.5 End-Stage Kidney Disease Treatment Cost Structure Analysis

      • 7.5.1 End-Stage Kidney Disease Treatment Raw Materials Analysis

      • 7.5.2 End-Stage Kidney Disease Treatment Labor Cost Analysis

      • 7.5.3 End-Stage Kidney Disease Treatment Manufacturing Expenses Analysis

    8 Global End-Stage Kidney Disease Treatment Import and Export Analysis (Top 10 Countries)

    • 8.1 Global End-Stage Kidney Disease Treatment Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global End-Stage Kidney Disease Treatment Export by Region (Top 10 Countries) (2017-2028)

    9 Global End-Stage Kidney Disease Treatment Market Outlook by Types and Applications to 2022

    • 9.1 Global End-Stage Kidney Disease Treatment Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global MK-3866 Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Pacritinib Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Sanguinate Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Tesidolumab Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Others Consumption and Growth Rate (2017-2022)

    • 9.2 Global End-Stage Kidney Disease Treatment Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Clinic Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Others Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise End-Stage Kidney Disease Treatment Market Analysis and Outlook till 2022

    • 10.1 Global End-Stage Kidney Disease Treatment Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.2.2 Canada End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.2.3 Mexico End-Stage Kidney Disease Treatment Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.3.2 UK End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.3.3 Spain End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.3.4 Belgium End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.3.5 France End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.3.6 Italy End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.3.7 Denmark End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.3.8 Finland End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.3.9 Norway End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.3.10 Sweden End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.3.11 Poland End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.3.12 Russia End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.3.13 Turkey End-Stage Kidney Disease Treatment Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.4.2 Japan End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.4.3 India End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.4.4 South Korea End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.4.5 Pakistan End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.4.6 Bangladesh End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.4.7 Indonesia End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.4.8 Thailand End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.4.9 Singapore End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.4.10 Malaysia End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.4.11 Philippines End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.4.12 Vietnam End-Stage Kidney Disease Treatment Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.5.2 Colombia End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.5.3 Chile End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.5.4 Argentina End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.5.5 Venezuela End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.5.6 Peru End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.5.7 Puerto Rico End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.5.8 Ecuador End-Stage Kidney Disease Treatment Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.6.2 Kuwait End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.6.3 Oman End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.6.4 Qatar End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.6.5 Saudi Arabia End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.6.6 United Arab Emirates End-Stage Kidney Disease Treatment Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.7.2 South Africa End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.7.3 Egypt End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.7.4 Algeria End-Stage Kidney Disease Treatment Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia End-Stage Kidney Disease Treatment Consumption (2017-2022)

      • 10.8.2 New Zealand End-Stage Kidney Disease Treatment Consumption (2017-2022)

    11 Global End-Stage Kidney Disease Treatment Competitive Analysis

    • 11.1 F Hoffmann-La Roche Ltd

      • 11.1.1 F Hoffmann-La Roche Ltd Company Details

      • 11.1.2 F Hoffmann-La Roche Ltd End-Stage Kidney Disease Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 F Hoffmann-La Roche Ltd End-Stage Kidney Disease Treatment Main Business and Markets Served

      • 11.1.4 F Hoffmann-La Roche Ltd End-Stage Kidney Disease Treatment Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 CTI BioPharma Corp

      • 11.2.1 CTI BioPharma Corp Company Details

      • 11.2.2 CTI BioPharma Corp End-Stage Kidney Disease Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 CTI BioPharma Corp End-Stage Kidney Disease Treatment Main Business and Markets Served

      • 11.2.4 CTI BioPharma Corp End-Stage Kidney Disease Treatment Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 BLR Bio LLC

      • 11.3.1 BLR Bio LLC Company Details

      • 11.3.2 BLR Bio LLC End-Stage Kidney Disease Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 BLR Bio LLC End-Stage Kidney Disease Treatment Main Business and Markets Served

      • 11.3.4 BLR Bio LLC End-Stage Kidney Disease Treatment Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 VESSL Therapeutics Ltd

      • 11.4.1 VESSL Therapeutics Ltd Company Details

      • 11.4.2 VESSL Therapeutics Ltd End-Stage Kidney Disease Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 VESSL Therapeutics Ltd End-Stage Kidney Disease Treatment Main Business and Markets Served

      • 11.4.4 VESSL Therapeutics Ltd End-Stage Kidney Disease Treatment Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Novartis AG

      • 11.5.1 Novartis AG Company Details

      • 11.5.2 Novartis AG End-Stage Kidney Disease Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Novartis AG End-Stage Kidney Disease Treatment Main Business and Markets Served

      • 11.5.4 Novartis AG End-Stage Kidney Disease Treatment Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Prolong Pharmaceuticals LLC

      • 11.6.1 Prolong Pharmaceuticals LLC Company Details

      • 11.6.2 Prolong Pharmaceuticals LLC End-Stage Kidney Disease Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Prolong Pharmaceuticals LLC End-Stage Kidney Disease Treatment Main Business and Markets Served

      • 11.6.4 Prolong Pharmaceuticals LLC End-Stage Kidney Disease Treatment Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    12 Global End-Stage Kidney Disease Treatment Market Outlook by Types and Applications to 2028

    • 12.1 Global End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global MK-3866 Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Pacritinib Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Sanguinate Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.4 Global Tesidolumab Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.5 Global Others Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Clinic Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise End-Stage Kidney Disease Treatment Market Analysis and Outlook to 2028

    • 13.1 Global End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.2.2 Canada End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.2.3 Mexico End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.3.2 UK End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.3.3 Spain End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.3.4 Belgium End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.3.5 France End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.3.6 Italy End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.3.7 Denmark End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.3.8 Finland End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.3.9 Norway End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.3.10 Sweden End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.3.11 Poland End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.3.12 Russia End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.3.13 Turkey End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.4.2 Japan End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.4.3 India End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.4.4 South Korea End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.4.8 Thailand End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.4.9 Singapore End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.4.11 Philippines End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.5.2 Colombia End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.5.3 Chile End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.5.4 Argentina End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.5.6 Peru End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.6.3 Oman End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.6.4 Qatar End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.7.2 South Africa End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.7.3 Egypt End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.7.4 Algeria End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand End-Stage Kidney Disease Treatment Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of End-Stage Kidney Disease Treatment

    • Figure of End-Stage Kidney Disease Treatment Picture

    • Table Global End-Stage Kidney Disease Treatment Import by Region (Top 10 Countries) (2017-2028)

    • Table Global End-Stage Kidney Disease Treatment Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global MK-3866 Consumption and Growth Rate (2017-2022)

    • Figure Global Pacritinib Consumption and Growth Rate (2017-2022)

    • Figure Global Sanguinate Consumption and Growth Rate (2017-2022)

    • Figure Global Tesidolumab Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Clinic Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global End-Stage Kidney Disease Treatment Consumption by Country (2017-2022)

    • Table North America End-Stage Kidney Disease Treatment Consumption by Country (2017-2022)

    • Figure United States End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Canada End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Mexico End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Table Europe End-Stage Kidney Disease Treatment Consumption by Country (2017-2022)

    • Figure Germany End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure UK End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Spain End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Belgium End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure France End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Italy End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Denmark End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Finland End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Norway End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Sweden End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Poland End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Russia End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Turkey End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Table APAC End-Stage Kidney Disease Treatment Consumption by Country (2017-2022)

    • Figure China End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Japan End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure India End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Korea End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Pakistan End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Indonesia End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Thailand End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Singapore End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Malaysia End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Philippines End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Vietnam End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Table South America End-Stage Kidney Disease Treatment Consumption by Country (2017-2022)

    • Figure Brazil End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Colombia End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Chile End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Argentina End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Venezuela End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Peru End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Ecuador End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Table GCC End-Stage Kidney Disease Treatment Consumption by Country (2017-2022)

    • Figure Bahrain End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Kuwait End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Oman End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Qatar End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Table Africa End-Stage Kidney Disease Treatment Consumption by Country (2017-2022)

    • Figure Nigeria End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Africa End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Egypt End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure Algeria End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Table Oceania End-Stage Kidney Disease Treatment Consumption by Country (2017-2022)

    • Figure Australia End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Figure New Zealand End-Stage Kidney Disease Treatment Consumption and Growth Rate (2017-2022)

    • Table F Hoffmann-La Roche Ltd Company Details

    • Table F Hoffmann-La Roche Ltd End-Stage Kidney Disease Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table F Hoffmann-La Roche Ltd End-Stage Kidney Disease Treatment Main Business and Markets Served

    • Table F Hoffmann-La Roche Ltd End-Stage Kidney Disease Treatment Product Portfolio

    • Table CTI BioPharma Corp Company Details

    • Table CTI BioPharma Corp End-Stage Kidney Disease Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table CTI BioPharma Corp End-Stage Kidney Disease Treatment Main Business and Markets Served

    • Table CTI BioPharma Corp End-Stage Kidney Disease Treatment Product Portfolio

    • Table BLR Bio LLC Company Details

    • Table BLR Bio LLC End-Stage Kidney Disease Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table BLR Bio LLC End-Stage Kidney Disease Treatment Main Business and Markets Served

    • Table BLR Bio LLC End-Stage Kidney Disease Treatment Product Portfolio

    • Table VESSL Therapeutics Ltd Company Details

    • Table VESSL Therapeutics Ltd End-Stage Kidney Disease Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table VESSL Therapeutics Ltd End-Stage Kidney Disease Treatment Main Business and Markets Served

    • Table VESSL Therapeutics Ltd End-Stage Kidney Disease Treatment Product Portfolio

    • Table Novartis AG Company Details

    • Table Novartis AG End-Stage Kidney Disease Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis AG End-Stage Kidney Disease Treatment Main Business and Markets Served

    • Table Novartis AG End-Stage Kidney Disease Treatment Product Portfolio

    • Table Prolong Pharmaceuticals LLC Company Details

    • Table Prolong Pharmaceuticals LLC End-Stage Kidney Disease Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Prolong Pharmaceuticals LLC End-Stage Kidney Disease Treatment Main Business and Markets Served

    • Table Prolong Pharmaceuticals LLC End-Stage Kidney Disease Treatment Product Portfolio

    • Figure Global MK-3866 Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Pacritinib Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Sanguinate Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Tesidolumab Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Clinic Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global End-Stage Kidney Disease Treatment Consumption Forecast by Country (2022-2028)

    • Table North America End-Stage Kidney Disease Treatment Consumption Forecast by Country (2022-2028)

    • Figure United States End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe End-Stage Kidney Disease Treatment Consumption Forecast by Country (2022-2028)

    • Figure Germany End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure France End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC End-Stage Kidney Disease Treatment Consumption Forecast by Country (2022-2028)

    • Figure China End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure India End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table South America End-Stage Kidney Disease Treatment Consumption Forecast by Country (2022-2028)

    • Figure Brazil End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC End-Stage Kidney Disease Treatment Consumption Forecast by Country (2022-2028)

    • Figure Bahrain End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa End-Stage Kidney Disease Treatment Consumption Forecast by Country (2022-2028)

    • Figure Nigeria End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania End-Stage Kidney Disease Treatment Consumption Forecast by Country (2022-2028)

    • Figure Australia End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand End-Stage Kidney Disease Treatment Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US